Zymeworks Presents Phase 1 Clinical Data for ZW191 at ESMO Congress 2026

Zymeworks presented Phase 1 clinical data for ZW191 at the ESMO Congress 2026, showing a confirmed objective response rate of 64.5% at a 6.4 mg/kg dose in patients with high-grade serous platinum-resistant ovarian cancer. The median duration of response is not yet reached, with a six-month progression-free survival rate of 61% based on a median follow-up of seven months. The company is also exploring strategic partnering opportunities with MTS Healthcare to fund further development of ZW191.